Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down – Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) gapped down prior to trading on Thursday . The stock had previously closed at $22.20, but opened at $21.08. Sarepta Therapeutics shares last traded at $21.1410, with a volume of 2,028,427 shares.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Bank of America boosted their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research report on Wednesday, October 22nd. Barclays dropped their target price on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 5th. Piper Sandler raised their price target on Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a report on Monday, August 25th. Finally, Guggenheim reduced their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $33.68.

Sarepta Therapeutics Price Performance

The company’s fifty day moving average price is $20.97 and its two-hundred day moving average price is $21.22. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -7.13 and a beta of 0.54.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The company’s revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.62 earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Inspire Investing LLC acquired a new position in Sarepta Therapeutics in the 1st quarter valued at $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Sarepta Therapeutics by 54.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock valued at $29,570,000 after acquiring an additional 164,041 shares during the period. Tempus Wealth Planning LLC grew its stake in shares of Sarepta Therapeutics by 475.8% in the second quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 17,070 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Sarepta Therapeutics by 21.8% during the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company’s stock worth $14,842,000 after acquiring an additional 155,358 shares during the period. Finally, Trexquant Investment LP bought a new position in Sarepta Therapeutics during the first quarter worth about $11,997,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.